KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Gross Profit (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Gross Profit for 13 consecutive years, with $188.6 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 27.36% to $188.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $644.4 million through Dec 2025, up 10.36% year-over-year, with the annual reading at $644.4 million for FY2025, 10.36% up from the prior year.
  • Gross Profit for Q4 2025 was $188.6 million at Supernus Pharmaceuticals, up from $173.1 million in the prior quarter.
  • The five-year high for Gross Profit was $188.6 million in Q4 2025, with the low at $114.5 million in Q2 2023.
  • Average Gross Profit over 5 years is $141.8 million, with a median of $143.2 million recorded in 2021.
  • The sharpest move saw Gross Profit decreased 23.48% in 2023, then soared 31.39% in 2024.
  • Over 5 years, Gross Profit stood at $142.1 million in 2021, then increased by 1.63% to $144.4 million in 2022, then rose by 0.22% to $144.7 million in 2023, then grew by 2.33% to $148.1 million in 2024, then grew by 27.36% to $188.6 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $188.6 million, $173.1 million, and $148.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.